• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

FDA Warning to Cannabidiol Suppliers


Pharmaceutical Executive

February 15, 2016.

FDA sent out eight warning letters on earlier this month to various makers of a dietary supplement called cannabidiol, which is derived from the Cannabis plant. Cannabidiol, also known as CBD oil, is described as a nonpsychoactive dietary supplement that is purported to have numerous benefits, including anti-inflammatory and antiemetic properties. 

However, FDA said the CBD oil products are being marketed as medications and have not been adequately tested to prove they are safe and effective. 

See more on this story at Pharmaceutical Technologyhere.

Recent Videos
Related Content